Skip to main content

Table 1 Baseline characteristics

From: Exhaled volatile organic compounds as novel biomarkers for early detection of COPD, asthma, and PRISm: a cross-sectional study

Variable

COPD (N = 184)

PRISm (N = 72)

Health (N = 45)

Asthma (N = 66)

P-values

Gender (%)

    

< 0.01

 Male

160 (87.0)

43 (59.7)

28 (62.2)

25 (37.9)

 Female

24 (13.0)

29 (40.3)

17 (37.8)

41 (62.1)

 BMI

23.5 ± 3.5

23.6 ± 4.0

22.9 ± 3.4

23.0 ± 3.9

0.67

 Age

68.5 ± 8.4

61.2 ± 13.6

55.5 ± 15.4

52.8 ± 13.7

< 0.01

Smoking condition

 Current smoking (%)

41(22.3)

19(26.4)

9(20)

8(12.1)

< 0.01

 Pack-day

1.2

1.1

0.7

0.54

< 0.01

 Occupational smoke exposure (%)

48 (26.1)

16 (22.2)

3 (6.7)

13 (19.7)

0.035

Underlying disease (%)

    

< 0.01

 Cardiovascular disease

62(33.7)

36(50)

3(6.7)

14(21.2)

 Digestive disease

5(2.7)

4(5.6)

2(4.4)

1(1.5)

 Others

36(19.6)

12(16.7)

2(4.4)

17(25.8)

Pulmonary functional test

 FEV1%

32.4 ± 20.9

59.9 ± 9.0

94 ± 13.4

71.1 ± 24.0

< 0.01

 FEV1/FVC

49.8 ± 15.6

82.7 ± 8.3

76.7 ± 6.2

68.8 ± 15.9

< 0.01

 IC

2.11 ± 0.6

2.52 ± 6.4

2.55 ± 3.2

2.4 ± 0.7

0.41

 MEF50

23.9 ± 16.4

51.82 ± 17.0

90.48 ± 24.2

45.6 ± 33.7

< 0.01

 MEF75

28.87 ± 18.2

82.4 ± 29.7

92.4 ± 19.5

49.5 ± 30.1

< 0.01

  1. Data are presented as n, mean ± sd or n (%), unless otherwise stated
  2. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity